Icosavax (ICVX) Stock Price, News & Analysis

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares.
View ICVX analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price targets for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they expect the company's share price to reach $26.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts.

Icosavax, Inc. (NASDAQ:ICVX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.81. The business had revenue of $1.83 million for the quarter, compared to analysts' expectations of $3.30 million.

Amplify Treatments, Testing and Advancements ETF holds 14,037 shares of ICVX stock, representing 0.78% of its portfolio.

Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.